Pegloticase to treat chronic gout that does not respond to conventional drugs
Gout is the most frequent cause of inflammatory arthritis worldwide. It results from high levels of urate and urate crystals being deposited in joints and other tissues.
Many people with gout respond well to conventional agents. But others are not as lucky and for them, pegloticase is an option, experts outline in Seminars in Arthritis & Rheumatism.
Pegloticase is a drug that profoundly lowers urate levels and crystals, reduces tender and swollen joint counts, decreases pain, and improves quality of life. It also brings down blood pressure.
It isn’t perfect, however, as pegloticase can cause an immune response, resulting in anti-drug antibodies that increase drug clearance so they don’t work as well.
But there are ways around this, the experts highlight, suggesting that “these reactions can be avoided by stopping pegloticase when there is a loss of serum urate lowering.”
Click here to read the original research.
Arthritis Digest Magazine was selected by Feedspot as one of the Top 5 Arthritis Blogs on the internet in 2019.
For more in-depth features, interviews and information, subscribe to Arthritis Digest magazine, a popular title that’s published six times a year. Click here for the digital version or tel 0845 643 8470 to order your had copy. You’ll know what your doctor is talking about, what new drugs are in the pipeline and be up to date on helpful products.